Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.
Frequently asked questions
What sector does Stella Pharma Corporation (4888) operate in?
Stella Pharma Corporation belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Stella Pharma Corporation (4888) current stock price?
As of the latest data, Stella Pharma Corporation stock price is ¥432, with a previous close of ¥432.
What is Stella Pharma Corporation (4888) current market capitalization?
Stella Pharma Corporation market cap is approximately 15.56 billion.
What is Stella Pharma Corporation (4888) Earnings Per Share (EPS)?
The trailing EPS is -¥23.
What is Stella Pharma Corporation (4888) EBITDA?
Stella Pharma Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -238.05 million.
Does Stella Pharma Corporation (4888) pay dividends?
No. Stella Pharma Corporation does not pay a dividend.
What is Stella Pharma Corporation (4888) beta (volatility) score?
Stella Pharma Corporation has a beta of 0.290, indicating lower volatility than the overall market.